Why BioNTech is Betting Big on Cancer Therapies Amidst a Strategic Shift
BioNTech is transitioning from pandemic defense to a focus on cancer treatment using mRNA technology. 2024 financial results show a profit decline to €1.08 per share, a reduction from €1.90,…